Drugs that target inflammation, synaptic dysfunction, insulin resistance, and oxidative stress, all of which lead to neuronal death and neurodegeneration, should also be considered for an effective therapeutic strategy for AD and PD. This evidence concerns the gene INS and Parkinson disease.